表面活性物质治疗急性肺损伤和急性呼吸窘迫综合征。
Surfactant therapy for acute lung injury and acute respiratory distress syndrome.
机构信息
Division of Acute Care Surgery, Department of Surgery, University of Michigan Health System, 1500 East Medical Center Drive, 1C340A-UH, SPC 5033, Ann Arbor, MI 48109-5033, USA.
出版信息
Crit Care Clin. 2011 Jul;27(3):525-59. doi: 10.1016/j.ccc.2011.04.005.
Abstract
This article examines exogenous lung surfactant replacement therapy and its usefulness in mitigating clinical acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS). Surfactant therapy is beneficial in term infants with pneumonia and meconium aspiration lung injury, and in children up to age 21 years with direct pulmonary forms of ALI/ARDS. However, extension of exogenous surfactant therapy to adults with respiratory failure and clinical ALI/ARDS remains a challenge. This article reviews clinical studies of surfactant therapy in pediatric and adult patients with ALI/ARDS, focusing on its potential advantages in patients with direct pulmonary forms of these syndromes.
摘要
本文探讨了外源性肺表面活性剂替代疗法及其在减轻临床急性肺损伤 (ALI) 和急性呼吸窘迫综合征 (ARDS) 方面的作用。表面活性剂疗法对患有肺炎和胎粪吸入性肺损伤的早产儿以及年龄在 21 岁以下的直接肺部 ALI/ARDS 患儿有益。然而，将外源性表面活性剂疗法扩展到患有呼吸衰竭和临床 ALI/ARDS 的成人仍然是一个挑战。本文回顾了外源性肺表面活性剂在儿科和成人 ALI/ARDS 患者中的临床研究，重点关注其在这些综合征的直接肺部形式患者中的潜在优势。
相似文献
1
Surfactant therapy for acute lung injury and acute respiratory distress syndrome.
Crit Care Clin. 2011 Jul;27(3):525-59. doi: 10.1016/j.ccc.2011.04.005.
2
Surfactant for pediatric acute lung injury.
Pediatr Clin North Am. 2008 Jun;55(3):545-75, ix. doi: 10.1016/j.pcl.2008.02.016.
3
The future of exogenous surfactant therapy.
Respir Care. 2011 Sep;56(9):1369-86; discussion 1386-8. doi: 10.4187/respcare.01306.
4
The role of surfactant treatment in preterm infants and term newborns with acute respiratory distress syndrome.
J Perinatol. 2009 May;29 Suppl 2:S18-22. doi: 10.1038/jp.2009.30.
5
Computed tomography assessment of exogenous surfactant-induced lung reaeration in patients with acute lung injury.
Crit Care. 2010;14(4):R135. doi: 10.1186/cc9186. Epub 2010 Jul 15.
6
Exogenous surfactant in paediatric Acute Lung Injury and Acute Respiratory Distress Syndrome.
Curr Drug Saf. 2006 May;1(2):159-68. doi: 10.2174/157488606776930553.
7
Clinical review: Exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome--where do we go from here?
Crit Care. 2012 Nov 22;16(6):238. doi: 10.1186/cc11512.
8
A shared protocol for porcine surfactant use in pediatric acute respiratory distress syndrome: a feasibility study.
BMC Pediatr. 2019 Jun 18;19(1):203. doi: 10.1186/s12887-019-1579-3.
9
Pediatric calfactant in acute respiratory distress syndrome trial.
Pediatr Crit Care Med. 2013 Sep;14(7):657-65. doi: 10.1097/PCC.0b013e3182917b68.
10
Advances with surfactant.
Emerg Med Clin North Am. 2008 Nov;26(4):921-8, viii. doi: 10.1016/j.emc.2008.08.001.
引用本文的文献
1
Safety and efficacy of pulmonary surfactant therapy for acute respiratory distress syndrome in children: a systematic review and meta-analysis.
BMC Pulm Med. 2025 May 21;25(1):250. doi: 10.1186/s12890-025-03728-4.
2
Surfactant protein SP-B: one ring to rule the molecular and biophysical mechanisms of the pulmonary surfactant system.
Biophys Rev. 2025 Mar 18;17(2):653-666. doi: 10.1007/s12551-025-01285-y. eCollection 2025 Apr.
3
Oxidative stress, redox status and surfactant metabolism in mechanically ventilated patients receiving different approaches to oxygen therapy (MecROX): An observational study protocol for mechanistic evaluation.
NIHR Open Res. 2024 Jul 8;4:23. doi: 10.3310/nihropenres.13567.2. eCollection 2024.
4
New experiments and models to describe soluble surfactant adsorption above and below the critical micelle concentration.
J Colloid Interface Sci. 2025 Jan;677(Pt A):557-568. doi: 10.1016/j.jcis.2024.07.204. Epub 2024 Jul 27.
5
Synergistic Therapeutic Effects of D-Mannitol-Cerium-Quercetin (Rutin) Coordination Polymer Nanoparticles on Acute Lung Injury.
Molecules. 2024 Jun 13;29(12):2819. doi: 10.3390/molecules29122819.
6
Mechanosensitive channels TMEM63A and TMEM63B mediate lung inflation-induced surfactant secretion.
J Clin Invest. 2024 Dec 21;134(5):e174508. doi: 10.1172/JCI174508.
7
Evolution of interfacial mechanics of lung surfactant mimics progression of acute respiratory distress syndrome.
Proc Natl Acad Sci U S A. 2023 Dec 19;120(51):e2309900120. doi: 10.1073/pnas.2309900120. Epub 2023 Dec 12.
8
Intrinsic pulmonary sealing, its mechanisms and impact on validity and translational value of lung sealant studies: a pooled analysis of animal studies.
J Thorac Dis. 2023 Sep 28;15(9):4703-4716. doi: 10.21037/jtd-23-180. Epub 2023 Aug 30.
9
Comparative efficacy of pulmonary surfactant in respiratory distress syndrome in preterm infants: a Bayesian network meta-analysis.
Arch Med Sci. 2020 Jul 11;19(5):1446-1453. doi: 10.5114/aoms.2020.97065. eCollection 2023.
10
HUB genes transcriptionally regulate lipid metabolism in alveolar type II cells under LPS stimulation.
Heliyon. 2023 Aug 25;9(9):e19437. doi: 10.1016/j.heliyon.2023.e19437. eCollection 2023 Sep.
本文引用的文献
1
Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury.
Am J Respir Crit Care Med. 2011 Apr 15;183(8):1055-61. doi: 10.1164/rccm.201009-1424OC. Epub 2010 Dec 10.
2
Dry powder aerosolization of a recombinant surfactant protein-C-based surfactant for inhalative treatment of the acutely inflamed lung.
Crit Care Med. 2010 Jul;38(7):1584-91. doi: 10.1097/CCM.0b013e3181dfcb3b.
3
Critical structural and functional roles for the N-terminal insertion sequence in surfactant protein B analogs.
PLoS One. 2010 Jan 13;5(1):e8672. doi: 10.1371/journal.pone.0008672.
4
Animal derived surfactant extract for treatment of respiratory distress syndrome.
Cochrane Database Syst Rev. 2009 Apr 15(2):CD007836. doi: 10.1002/14651858.CD007836.
5
Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome.
Cochrane Database Syst Rev. 2009 Jan 21(1):CD000141. doi: 10.1002/14651858.CD000141.pub2.
6
The use of surfactant in lung transplantation.
Transplantation. 2008 Dec 15;86(11):1554-9. doi: 10.1097/TP.0b013e31818a8418.
7
Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.
Curr Med Chem. 2008;15(19):1911-24. doi: 10.2174/092986708785132942.
8
Surfactant for pediatric acute lung injury.
Pediatr Clin North Am. 2008 Jun;55(3):545-75, ix. doi: 10.1016/j.pcl.2008.02.016.
9
Aerosolized beta-adrenergic agonist therapy reduces pulmonary edema following lung surgery.
Chest. 2008 Apr;133(4):833-5. doi: 10.1378/chest.07-2788.
10
Surfactant dysfunction in lung contusion with and without superimposed gastric aspiration in a rat model.
Shock. 2008 Nov;30(5):508-17. doi: 10.1097/SHK.0b013e3181673fc5.
Zotero 插件